Is the onset of adverse effects of immunotherapy always bad news for the patients…?—certainly not!

Despite the identification of promising and validated biomarkers the response to immunotherapy can be unexpected or variable, including rapid regression (complete or partial) of the tumor mass, stability, progression, pseudo progression or hyper tumor progression (1-5). Immunotherapy, in general, is less toxic than chemotherapy for patients with cancer. However, the side effects [adverse events (AE)] linked to these new treatments [treatment-related adverse events (trAEs)] are often described and have variable severity (6). Stimulation of an immune response by checkpoint inhibitors can lead, in particular, to side effects of immunological origin [immune-related adverse events (irAEs)], which are variable depending on the series, the therapeutic molecule, the pathology, the tumor and the patient (6). These irAEs cause the formation of lesions in one or different organs according to the patient with very variable consequences (6-10). While immunotherapy and most of the AEs are relatively well tolerated the irAEs are sometimes very severe running a risk of death of the patient, leading rapid and adapted therapeutic care (9,11-13).

Lisberg et al., showed that the emergence of trAEs in a cohort of patients receiving first-line treatment with pembrolizumab for advanced stage or metastatic non-small cell lung carcinoma (NSCLC) correlated with, a better tumor response, a better survival free progression and longer overall survival, compared to patients who did not experience trAEs (14). This mono centric (University of California) and retrospective study concerned analyses from 97 patients included in the KEYNOTE-001 (clinicaltrials.govNCT01295827), which contained a total of 495 patients from several centers (14,15). In the study performed by Lisberg et al., the most frequent AEs were fatigue (50%), pain (36%) and dyspnea (29%) (14). This study included all the trAEs) and not only those defined as irAEs. Among 94/97 (97%) patients one or several AEs were reported for a total of 826 AEs (14). In fact, only 85/826 (10%) of these AEs occurring in 39/97 (40%) patients were considered by the investigators as being trAEs (14). The results obtained with the cohort of patients hospitalized in a single center were different from of the total cohort of patients included in the KEYNOTE 001 since more than 71% of trAE were reported in the latter (14,15). This difference can be explained by the increased experience of investigators of the University of California with the use of immunotherapy and the better identification of side effects associated to treatment (14). Other explanations were put forward to explain this difference, including the epidemiological factors of patients, the fact that the cohort of the University of California contained, for example, more non-smoking patients (14).

Several recent studies have shown that irAEs of patients with metastatic NSCLC with second-line immunotherapy showed better survival free progression and longer overall survival than those of patients without irAEs survival (16-18). The study of Ricciuti et al. reported that stage IV NSCLC patients treated with second-line nivolumab who experienced one or two irAEs had a survival of 11.9 or 26.8 months, respectively compared to survival for 4.6 months for patients who did not experience irAEs (17). In this series some irAEs (skin and hepatic-gallbladder reactions) were not associated with longer overall survival in opposition to other irAEs (lung, endocrine and gastro-intestinal reactions) (17). In contrast, Suresh et al. recently reported results showing that the development of checkpoint inhibitor pneumonitis (CIP) when on immunotherapy was associated with shorter overall survival (19). It is noteworthy that the frequency of CIP was evaluated at 3–5% of patients receiving immunotherapy, but this frequency is probable underestimated (20).

It is interesting to note that the number and severity of the irAEs arising in a population of elderly patients (more than 70 years old) with NSCLC treated with immunotherapy appeared to be identical to that of a population of patients less than 60 years old, even if the elderly patients benefited less from this treatment (21). The biological mechanisms behind this difference still remain uncertain and need to be investigated. A number of studies are ongoing and are being developed to better understand the molecular and biological origins of the occurrence of irAEs in response to therapy (22). Prediction of the onset (and the potential severity) of irAEs depending on the administered therapeutic molecule may participate in the development of new predictive biomarkers of therapeutic efficacy. It is within this context that factors predictive of the emergence of irAEs have been studied based on the clinical and biological data, taken individually or in association (6,23,24). These factors include the sex of the patient, auto-immune diseases or allergies, the level of circulating eosinophils, corticoid treatment, gene expression of CD177, the plasma level of interleukin 17, a score combining several plasma cytokines, analysis of the microbiome, …. (6,23,24). The analysis of the repertoire of TCR of T lymphocytes of tissues and/or blood is of particular interest in predicting the emergence and severity of irAEs and/or the therapeutic response and is strongly investigated currently (25,26).

Finally, the study by Lisberg et al. shows how difficult it is to define and diagnose AEs of patients treated with immunotherapy and to distinguish among the AEs those that are irAEs (14). The frequency and severity of the AEs of patients can be very variable depending on the treatment, the cancer type but also the expertise and evaluation of the physicians (14). The study by Lisberg et al. confirms that the presence but also the number of trAEs the patient experiences, strongly correlate with increased efficacy of immunotherapy of patients with advanced stage or metastatic NSCLC.

Acknowledgements

The author wishes to thank the Ligue Départementale 06, the Conseil Départemental des Alpes Maritimes, and the Cancéropôle PACA for their support.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

References

1. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol 2018;4:1543-52. [Crossref] [PubMed]
2. Hofman P. PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Rev Mol Diagn 2017;17:1097-108. [Crossref] [PubMed]
3. Heeke S, Hofman P. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? Transl Lung Cancer Res 2018;7:631-8. [Crossref] [PubMed]
4. Knorr DA, Ravetch JV. Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism. Clin Cancer Res 2019;25:904-6. [Crossref] [PubMed]
5. Wong AS, Thian YL, Kapur J, et al. Pushing the limits of immune-related response: a case of “extreme pseudoprogression”. Cancer Immunol Immunother 2018;67:1105-11. [Crossref] [PubMed]
6. Sosa A, Lopez Cadena E, Simon Olive C, et al. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 2018;10:1758835918764628. [Crossref] [PubMed]
7. Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 2019;40:17-65. [PubMed]
8. Petrelli F, Ardito R, Borgonovo K, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 2018;103:7-16. [Crossref] [PubMed]
9. Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis 2018;10:S480-9. [Crossref] [PubMed]
10. Yang S, Asnani A. Cardiotoxicities associated with immune checkpoint inhibitors. Curr Probl Cancer 2018;42:422-32. [Crossref] [PubMed]
11. Bhandari S, Gill AS, Perez CA, et al. Management of immunotherapy toxicities in older adults. Semin Oncol 2018;45:226-31. [Crossref] [PubMed]
12. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv264-6. [Crossref] [PubMed]
13. Thompson JA. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. J Natl Compr Canc Netw 2018;16:594-6. [Crossref] [PubMed]
14. Lisberg A, Tucker DA, Goldman JW, et al. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunol Res 2018. [Epub ahead of print]. [Crossref] [PubMed]
15. Garon EB, Rizvi NA, Hui R, Leighl N, et al. KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. [Crossref] [PubMed]
16. Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol 2018;4:374-8. [Crossref] [PubMed]
17. Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 2019;145:479-85. [Crossref] [PubMed]
18. Teraoka S, Fujimoto D, Morimoto T, et al. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol 2017;12:1798-805. [Crossref] [PubMed]
19. Suresh K, Psoter KJ, Voong KR, et al. Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy. J Thorac Oncol 2019;14:494-502. [Crossref] [PubMed]
20. Suresh K, Naidoo J, Lin CT, et al. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest 2018;154:1416-23. [Crossref] [PubMed]
21. Lichtenstein M, Nipp RD, Muzikansky A, et al. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2018. [Epub ahead of print]. [PubMed]
22. Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res 2018;6:1445-52. [Crossref] [PubMed]
23. Kartolo A, Sattar J, Sahai V, et al. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol 2018;25:e403-10. [Crossref] [PubMed]
24. Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res 2019;25:1557-63. [Crossref] [PubMed]
25. Hogan SA, Courtier A, Cheng PF, et al. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res 2019;7:77-85. [Crossref] [PubMed]
26. Oh DY, Cham J, Zhang L, et al. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res 2017;77:1322-30. [Crossref] [PubMed]